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Abstract: We examined whether pramipexole (PPX) can inﬂ  uence depressive scale in normal 
and mild depressive parkinsonian patients. In an open study of PPX as an add-on to L-dopa 
therapy or single administration, 36 nondemented outpatients with Parkinson’s disease (PD) 
were entered ﬁ  rst. All were in the stage II or III of Hoehn and Yahr scale (H&Y). PPX were 
started at 0.125 mg/day and daily doses were increased to 1.5 mg/day. At 3 months after 
PPX treatment, patients were re-evaluated. Hamilton Depression Rating Scale (HAM-D), 
Uniﬁ  ed Parkinson’s Disease Rating Scale III, H&Y stage, and freezing of gait questionnaire 
were compared in patients before and after PPX treatment. These scores were signiﬁ  cantly 
improved after PPX administration. There were no correlations between HAM-D and those 
motor functions. We suggest that PPX treatment has antidepressant effects in depressive 
PD patients and also ameliorates HAM-D score in nondepressive PD patients in addition to 
motor function.
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Introduction
Depression occurs in about 40%–45% of patients with Parkinson’s disease (PD) and 
reduces both the subjective and objective quality of life independent of motor deﬁ  cits 
(Cummings et al 1999; Kupio et al 2000). Depressive symptoms precede those of 
motor function in 12%–37% of patients with PD (Taylor et al 1986). The pathologi-
cal feature of PD reveals degeneration of dopaminergic neurons in the striato-nigral 
system. In addition, the limbic system is also involved in PD (Lemke et al 2004). 
Pramipexole (PPX), D2/D3 receptor agonist acts on D3 versus D2 receptors in the 
regions of the brain that play a key role in the etiology of depression (Mayberg et al 
1995). These mechanisms could explain the effectiveness of PPX on depression in 
animal experiments (Willner et al 1994; Maj et al 1997) and in patients with major 
depressive disorder (Szegedi et al 1997; Corrigan et al 2000).
Recent European studies show that PPX treatment is beneﬁ  cial for patients 
with depression and PD and PPX is more effective on depression in PD as com-
pared with sertraline, an antidepressant (Rektorova et al 2003; Barone et al 2006). 
Furthermore, patients with refractory bipolar depression were treated with PPX 
as add-on therapy to various mood stabilizers (Goldberg et al 2004; Zarate et al 
2004; Aiken 2007).
Thus, the antidepressant effect of PPX in patients with a major depressive 
disorder has already been studied and PPX seems to be more powerful compared 
with other ergoline preparations such as bromocriptine, pergolide, and cabelgoline 
(Boyd 1995; Reeves et al 1997; Baeza et al 2002; Rektorova et al 2003). In this 
paper we studied how PPX treatment inﬂ  uences depressions and motor scales in 
PD patients.Neuropsychiatric Disease and Treatment 2008:4(4) 708
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Materials and methods
All patients underwent neurological evaluation. We included 
patients with idiopathic PD according to the UK Parkinson’s 
Disease Society Brain Bank Clinical Diagnostic Criteria 
(Daniel et al 1993), and obtained informed consent. The 
duration of the trial was from March 1st to July 31st 2006. 
In this prospective, observational, open study, patients with 
moderate and severe depressive episode deﬁ  ned according 
to the 10th revision of the International Classiﬁ  cation of 
Diseases were excluded for administration of PPX. In an 
open study of PPX as an add-on to L-dopa therapy or single 
administration, PPX was started at 0.125 mg/day and daily 
doses were increased to 1.5 mg/day. Patients on L-dopa 
therapy continued to take the same dosage of levodopa which 
was kept ﬁ  xed during the study. At 3 months after PPX 
treatment, patients were re-evaluated. Hamilton Depres-
sion Rating Scale (HAM-D) (Hamilton 1960), Uniﬁ  ed 
Parkinson’s Disease Rating Scale (UPDRS) III (Fahn et al 
1987), Hoehn and Yahr (H&Y) stage (Hoehn et al 1967), and 
freezing of gait questionnaire (FOGQ) (Giladi et al 2000) 
were compared in patients before and after PPX treatment. 
Statistical analysis used Wilcoxon signed rank test, Kruskal 
Wallis test, with SPSS for Windows version 13.0 (SPSS 
Inc., Chicago, IL, USA).
Results
Initially 36 PD outpatients without dementia were entered. 
A total of 31 patients (16 women and 15 men) were eli-
gible for this trial. The clinical background of 31 patients 
(16 women and 15 men) is shown in Table 1. Drop-outs 
due to adverse events occurred in 3 patients (nausea, 
aggravation of dyskinesia), but all were not serious, and 2 
patients moved to another town. The mean age (SD) was 
71.2 (8.3) years (70.9 [8.6] in women and 71.4 [8.2] in 
men). The mean disease duration (SD) was 4.4 (7.3) years 
(4.0 [3.9] in women and 4.7 [3.6] in men). All were able 
to walk independently (H&Y stage II or III). Twenty-nine 
patients received L-dopa. Two patients had PPX alone. 
None were treated with any antidepressants. Changes 
of neurological evaluation were shown in Table 2. After 
PPX administration, HAM-D score was declined. Motor 
function scores were also signiﬁ  cantly improved. There 
were no statistical correlations among HAM-D, UPDRS 
III, H&Y stage, and FOGQ.
Discussion
We excluded patients with moderate and severe depres-
sive episode. PPX doses used were lower than 1.5 mg/day. 
Those relative low doses of PPX improved HAM-D score 
signiﬁ  cantly. In relationship between other dopamine 
agonists and mental changes, bromocriptine worsened 
psychotic symptoms in patients suffering from schizo-
phrenia, other psychotic disorders, or psychotic depres-
sion (Pearson 1981). Cabergoline can be used similarly to 
bromocriptine in PD, and only a few reports discussed the 
efﬁ  cacy of use in psychotic symptoms (Baeza et al 2002). 
Pergolide is well used in PD, but this dopamine agonist is 
reported to have no efﬁ  cacy on depression in PD patients 
by national multicenter prospective randomized studies 
(Rektorova et al 2003). In contrast, ropinirole, which is 
a nonergot dopamine agonist, as well as PPX showed an 
antidepressant effect, but no reports showed a comparison 
of antidepressant efﬁ  ciency between ropinirole and PPX 
(Pahwa et al 2007).
PPX had signiﬁ  cantly improved not only depressive 
parkinsonian patients but also bipolar depression (Corrigan 
et al 2000; Goldberg et al 2004; Zarate et al 2004). PPX 
was well tolerated and was signiﬁ  cantly more effective in 
reducing severity of depression and increasing numbers 
of responders (Goldberg et al 2004; Zarate et al 2004). 
These effects may relate to PPX’s preference for D3 versus 
D2 receptors and neurotrophic properties. Furthermore, 
D3 receptors may have an anatomic distribution which 
plays an important role in neuronal circuits implicated in 
depressive states.
According to a detailed survey of antidepressant drugs 
in PD by the Parkinson Study Group in the USA (Richard 
et al 2000), the administration of selective serotonin 
reuptake inhibitors (SSRI) usually serves as the ﬁ  rst-choice 
treatment.
Corrigan and colleagues (2000) reported that PPX for 
patients with major depression at the 1.0 mg per day dose 
had significantly improvement over baseline compared 
to the placebo measure of the HAM-D, Montgomery-
Asberg Depression Rating Scale, and Clinician’s Global 
Impressions – Severity of Illness scale, and the most obvious 
Table 1 Clinical background of patients
 Total  Women  Men
Age (years)  71.2 (8.3)  70.9 (8.6)  71.4 (8.2)
Duration of disease (years)  4.4 (7.3)  4.0 (3.9)  4.7 (3.6)
H&Y stage  2.5 (0.6)  2.5 (0.7)  2.5 (0.5)
L-dopa doses (mg/day)  217.7 (91.8)  190.6 (100.4)  246.7 (74.3)
Pramipexole doses (mg/day)  1.1 (0.5)  1.1 (0.5)  1.1 (0.5)
Notes: Data are shown as mean (SD).Neuropsychiatric Disease and Treatment 2008:4(4) 709
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improvement was seen in the PPX 5.0 mg group, although a 
substantial dropout rate increased (Corrigan et al 2000). A 
recent European study reported that PPX is more effective 
on depression in PD as compared with the antidepressant 
sertraline (Barone et al 2006).
In the present study, the HAM-D score was reduced 
during treatment with PPX and those antidepressant effects 
did not depend on motor function scale. Previous European 
experience (Lemke et al 2006) and our studies suggest that 
PPX has beneﬁ  ts for depressive symptoms in PD patients. 
These results support that the original serotonergic and 
noradrenergic hypotheses do not fully account for the 
neurobiology of depression or mechanism of action of 
effective antidepressants. Roy and colleagues (1985) found 
lower cerebrospinal ﬂ  uid homovanillic acid (HVA) which 
was known as dopamine metabolite in depressed subjects 
than in normal subjects. Also, direct measurement of brain 
monoamine metabolites from the internal jugular vein of 
treatment-resistant depressed patients revealed low HVA 
levels that were highly correlated with illness severity 
(Lambert et al 2000).
Thus, these results support the monoaminergic theories 
of depression, which hold that dysregulation of systems 
involving dopamine, in addition to serotonin and nor-
epinephrine, may be involved in major depression. The 
mechanism of action of currently available antidepressants 
is to re-equilibrate one or more neurotransmitter systems and 
restore relative efﬁ  ciency at one or more synaptic sites, such 
as by altering postsynaptic receptor sensitivity (Siever et al 
1985; Willner et al 2005). It is believed that PPX acts as a 
direct agonist at the postsynaptic receptor, thereby relieving 
some symptoms of depression.
Since the HAM-D score and motor function were 
improved after administration of PPX, and there was no cor-
relation between HAM-D and motor functions, this indicates 
improvement of HAM-D score was not due to an improve-
ment in motor functions.
We conclude that PPX is a useful strategy in improving 
of depressive state in PD. Further long-term study of PPX 
is needed to determine whether this dopamine agonist can 
prevent upcoming depression in PD.
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